Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ascentage Approved to Start China Trial of Apoptosis Candidate for Pancreatic Cancer

publication date: Feb 24, 2020

Ascentage Pharma of Suzhou is approved to start a China Phase Ib/II clinical trial of APG-1387, a novel small molecule IAP inhibitor that induces apoptosis. APG-1387 will be tested together with chemotherapy in patients with advanced pancreatic cancer. In preclinical tests, the candidate inhibited the growth of tumor cells, either as a monotherapy or in combination with targeted agents or chemotherapies. APG-1387 is the first IAP inhibitor to start China clinical trials. Ascentage develops novel therapies for cancers, chronic hepatitis B and age-related diseases. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China